Deanna J. Friedman-Klabanoff

Infectious Disease
120 Penn St
Baltimore, MD 21201

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

AGS-v PLUS, a Mosquito Salivary Peptide Vaccine, Modulates the Response to Aedes Mosquito Bites in Humans.

AGS-v PLUS, a Mosquito Salivary Peptide Vaccine, Modulates the Response to Aedes Mosquito Bites in Humans.

Journal: Vaccines
Published: July 18, 2025

Controlled human malaria infection with NF54 and 7G8 strains elicit differential antibody responses to Plasmodium falciparum peptides.

Controlled human malaria infection with NF54 and 7G8 strains elicit differential antibody responses to Plasmodium falciparum peptides.

Journal: Frontiers in immunology
Published: June 04, 2025

Vaccine-Induced Antibodies to a C-Terminal Plasmodium falciparum Circumsporozoite Protein Epitope Associated With Protection Against Malaria Challenge.

Vaccine-Induced Antibodies to a C-Terminal Plasmodium falciparum Circumsporozoite Protein Epitope Associated With Protection Against Malaria Challenge.

Journal: The Journal of infectious diseases
Published: March 26, 2025

Malaria prevention in children: an update.

Malaria prevention in children: an update.

Journal: Current opinion in pediatrics
Published: February 01, 2024

Assessment of sociodemographic factors associated with time to self-reported COVID-19 infection among a large multi-center prospective cohort population in the southeastern United States.

Assessment of sociodemographic factors associated with time to self-reported COVID-19 infection among a large multi-center prospective cohort population in the southeastern United States.

Journal: PloS one
Published: October 18, 2023

Recombinant Full-length Plasmodium falciparum Circumsporozoite Protein-Based Vaccine Adjuvanted With Glucopyranosyl Lipid A-Liposome Quillaja saponaria 21: Results of Phase 1 Testing With Malaria Challenge.

Recombinant Full-length Plasmodium falciparum Circumsporozoite Protein-Based Vaccine Adjuvanted With Glucopyranosyl Lipid A-Liposome Quillaja saponaria 21: Results of Phase 1 Testing With Malaria Challenge.

Journal: The Journal of infectious diseases
Published: August 26, 2023

Persistence of antibody responses to COVID-19 vaccines among participants in the COVID-19 Community Research Partnership.

Persistence of antibody responses to COVID-19 vaccines among participants in the COVID-19 Community Research Partnership.

Journal: Vaccine: X
Published: August 07, 2023

Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March-October, 2021.

Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March-October, 2021.

Journal: Vaccine
Published: December 12, 2022

Factors associated with COVID-19 vaccination during June-October 2021: A multi-site prospective study.

Factors associated with COVID-19 vaccination during June-October 2021: A multi-site prospective study.

Journal: Vaccine
Published: October 14, 2022

Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial.

Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial.

Journal: EBioMedicine
Published: August 13, 2022

Vaccine-induced seroconversion in participants in the North Carolina COVID-19 community Research Partnership.

Vaccine-induced seroconversion in participants in the North Carolina COVID-19 community Research Partnership.

Journal: Vaccine
Published: May 16, 2022

Comparison of Racial, Ethnic, and Geographic Location Diversity of Participants Enrolled in Clinic-Based vs 2 Remote COVID-19 Clinical Trials.

Comparison of Racial, Ethnic, and Geographic Location Diversity of Participants Enrolled in Clinic-Based vs 2 Remote COVID-19 Clinical Trials.

Journal: JAMA network open
Published: February 14, 2022
Showing 1-12 of 19

Last Updated: 09/26/2026